Saturday, 25 November 2017
Latest news
Main » Sangamo Therapeutics, Inc. (SGMO) Posts Earnings Results, Beats Estimates By $0.04 EPS

Sangamo Therapeutics, Inc. (SGMO) Posts Earnings Results, Beats Estimates By $0.04 EPS

11 November 2017

33 funds opened positions while 37 raised stakes. During last 3 month period, 0.66% of total institutional ownership has changed in the company shares.

It is helpful for everyday investors to find out what portion of a public company's shares outstanding are held by institutional investors, in particular. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.04, Briefing.com reports. New York State Common Retirement Fund owned about 0.11% of Sangamo Therapeutics worth $671,000 at the end of the most recent reporting period. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) earned "Hold" rating by Piper Jaffray on Thursday, August 10. Given that its average daily volume over the 30 days has been 1.72 million shares a day, this signifies a pretty significant change over the norm. Nelson Roberts Investment Advsrs Ltd Liability Company accumulated 0.01% or 3,000 shares. Panagora Asset Mgmt holds 2,693 shares. Finally, Wells Fargo & Company reissued an "outperform" rating and set a $30.00 target price (up previously from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Susquehanna International Grp Limited Liability Partnership invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Meeder Asset Mngmt has 592 shares. Swiss National Bank boosted its stake in shares of Sangamo Therapeutics by 26.4% during the 2nd quarter.

Since May 11, 2017, it had 0 insider buys, and 1 sale for $13,600 activity. Jefferies reinitiated Sangamo Therapeutics Inc (NASDAQ:SGMO) on Thursday, June 22 with "Buy" rating. Therefore 44% are positive. The stock was trading at a distance of -18.79% from its 52-week highs and stands 422.64% away from its 52-week lows.

More news: Delhi air pollution: United suspends flights to capital, cites 'severe weather'

DENTSPLY SIRONA Inc (XRAY) formed multiple top with $70.32 target or 9.00% above today's $64.51 share price. SGMO was included in 17 notes of analysts from August 8, 2015. The stock presently has a consensus rating of "Hold" and a consensus price target of $14.40. The rating was maintained by Jefferies on Tuesday, September 12 with "Buy". (SGMO) is BLACKROCK INC., which now holds 5,624,563 shares. The company was downgraded on Wednesday, October 19 by PiperJaffray. The rating was maintained by JP Morgan with "Buy" on Thursday, September 3. The rating was downgraded by Piper Jaffray on Wednesday, October 19 to "Neutral". After a recent check, it is observed that the insiders for the firm now own 1.91% shares. Northern Trust Corporation has invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). The firm has "Buy" rating by Jefferies given on Friday, October 23.

Looking into last 5 trades, the stock observed a return of nearly 1.65%.

Aveo Pharmaceuticals (NASDAQ:AVEO)'s share price soared 2.46% or 0.07 to reach at $2.92 during previous trading session. Sangamo Therapeutics Inc (NASDAQ:SGMO) has risen 29.78% since November 10, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.

More news: Mahindra Logistics shares fall over 2% on market debut

Heading into the stock price potential, Sangamo Therapeutics, Inc.by far traveled -7.95% after crossing its median price target of $11.

Total shares held by institutions as of the most recent company filings are 53,417,489 with a reported 5,830,498 bought and 2,691,067 sold. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The business's quarterly revenue was up 124.3% compared to the same quarter last year. equities research analysts predict that Sangamo Therapeutics, Inc. will post -0.85 earnings per share for the current year. The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

More news: How Will The Louis CK Scandal Affect The Future Of FX?